Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy

Shayan Dioun, Ling Chen, Alexandre Buckley De Meritens, Caryn M. St. Clair, June Y. Hou, Fady Khoury-Collado, Tarah Pua, Dawn L. Hershman, Jason D. Wright

Producción científica › revisión exhaustiva

1 Cita (Scopus)

Huella

Profundice en los temas de investigación de 'Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy'. En conjunto forman una huella única.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science